Shengchun Kong

IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

Mark A. Socinski, Makoto Nishio, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2021 · 523 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

Frank Griesinger, Giuseppe Curigliano, Michael Thomas et al. · Annals of Oncology · 2022 · 178 citations · Full text

Medicine, Oncology, Pharmacology +16

Changes in Iron Measures over Menopause and Associations with Insulin Resistance

Catherine Kim, Bin Nan, Shengchun Kong et al. · Journal of Women s Health · 2012 · 48 citations · Full text

Medicine, Endocrinology, Epidemiologic Methods +16

Racial/Ethnic Differences in Sex Hormone Levels among Postmenopausal Women in the Diabetes Prevention Program

Catherine Kim, Sherita Hill Golden, Kieren J. Mather et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 40 citations · Full text

Medicine, Endocrinology, Preventive Medicine +14

Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups

Mark A. Socinski, Tony Mok, Makoto Nishio et al. · Cancer Research · 2020 · 39 citations

Medicine, Oncology, Pharmacology +13